News

Owen Sharp, Chief Executive of Prostate Cancer UK (formerly The Prostate Cancer Charity) comments on NICE's final decision to recommend breakthrough prostate cancer drug abiraterone for routine use on the NHS in England & Wales.

The Prostate Cancer Charity expresses disappointment at the National Institute of Clinical Excellence's (NICE) decision to reverse its recommendation that denosumab be made available on the NHS in England and Wales to help minimise the risk of complications once prostate cancer has spread to a man's bones.

The Prostate Cancer Charity today released the results of its ground-breaking survey which asked men with prostate cancer how they feel about the care and support they receive.